<DOC>
	<DOC>NCT01068613</DOC>
	<brief_summary>This study will assess the bronchodilator effects of multiple doses of QAX028 at two different dose levels when compared to tiotropium and placebo in a COPD population.</brief_summary>
	<brief_title>Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis of COPD according to GOLD guidelines Postbronchodilator 30%â‰¤FEV1&lt;80% of predicted normal and ostbronchodilator FEV1/FVC &lt;0.7 Smoking history of at least 10 pack years Requiring oxygen therapy on a daily basis Exacerbation of airway disease in the 6 weeks prior to screening or between screening and dosing Lung reduction surgery Respiratory tract infection in the 6 weeks prior to screening Significant cardiac history History of asthma with onset of symptoms prior to age 40 years Active use of certain COPD medications, beta blockers Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Long acting muscarinic antagonist</keyword>
</DOC>